Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CUE NASDAQ:PBYI NASDAQ:SNDL NASDAQ:SRZN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCUECue Biopharma$25.33-14.0%$231.49$4.97▼$41.42$116.22M2.371.45 million shs160,873 shsPBYIPuma Biotechnology$7.19+0.3%$6.86$2.85▼$7.90$364.95M1.24296,945 shs251,403 shsSNDLSNDL$1.46+3.5%$1.43$1.15▼$2.89$362.93M0.883.05 million shs2.20 million shsSRZNSurrozen$29.87-0.9%$28.76$5.90▼$35.00$349.94M0.59110,545 shs14,861 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCUECue Biopharma-14.05%-29.11%-93.57%-90.82%-96.22%PBYIPuma Biotechnology+0.28%-0.96%-5.02%+5.43%+147.93%SNDLSNDL+3.55%+0.69%+1.39%-2.67%+14.06%SRZNSurrozen-0.90%-2.86%-6.22%+22.02%+359.54%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCUECue Biopharma$25.33-14.0%$231.49$4.97▼$41.42$116.22M2.371.45 million shs160,873 shsPBYIPuma Biotechnology$7.19+0.3%$6.86$2.85▼$7.90$364.95M1.24296,945 shs251,403 shsSNDLSNDL$1.46+3.5%$1.43$1.15▼$2.89$362.93M0.883.05 million shs2.20 million shsSRZNSurrozen$29.87-0.9%$28.76$5.90▼$35.00$349.94M0.59110,545 shs14,861 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCUECue Biopharma-14.05%-29.11%-93.57%-90.82%-96.22%PBYIPuma Biotechnology+0.28%-0.96%-5.02%+5.43%+147.93%SNDLSNDL+3.55%+0.69%+1.39%-2.67%+14.06%SRZNSurrozen-0.90%-2.86%-6.22%+22.02%+359.54%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCUECue Biopharma 1.00SellN/AN/APBYIPuma Biotechnology 2.00HoldN/AN/ASNDLSNDL 1.67Reduce$5.00242.47% UpsideSRZNSurrozen 2.80Moderate Buy$42.0040.61% UpsideCurrent Analyst Ratings BreakdownLatest CUE, SNDL, PBYI, and SRZN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/11/2026PBYIPuma Biotechnology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C+) ➝ Hold (C)5/7/2026SRZNSurrozen HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$36.00 ➝ $44.004/29/2026SNDLSNDL Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell4/21/2026PBYIPuma Biotechnology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C+)4/21/2026SRZNSurrozen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026SRZNSurrozen TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy3/27/2026CUECue Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/24/2026SRZNSurrozen Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$40.003/24/2026SRZNSurrozen HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$32.00 ➝ $36.002/19/2026SRZNSurrozen Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$40.002/19/2026SRZNSurrozen Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$40.00(Data available from 5/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCUECue Biopharma$27.47M3.63N/AN/A$10.08 per share2.51PBYIPuma Biotechnology$228.40M1.60$0.84 per share8.59$2.52 per share2.85SNDLSNDL$937.39M0.40$0.12 per share12.52$3.08 per share0.47SRZNSurrozen$3.48M99.65N/AN/A($23.96) per share-1.25Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCUECue Biopharma-$26.60M-$9.61N/AN/AN/A-96.85%-165.19%-77.77%N/APBYIPuma Biotechnology$31.11M$0.4814.9837.84N/A10.69%20.30%12.05%N/ASNDLSNDL-$11.29M-$0.03N/A36.50N/A-1.19%-1.02%-0.85%7/30/2026 (Estimated)SRZNSurrozen-$242.03M-$37.59N/AN/AN/A-4,810.50%-4,055.04%-154.08%N/ALatest CUE, SNDL, PBYI, and SRZN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026CUECue BiopharmaN/A-$1.08N/A-$1.08N/A$5.69 million5/7/2026Q1 2026PBYIPuma Biotechnology-$0.13-$0.04+$0.09-$0.07$42.00 million$44.81 million5/6/2026Q1 2026SRZNSurrozen-$1.0920-$11.65-$10.5580-$11.65$4.00 million$5.00 million3/23/2026Q4 2025SRZNSurrozen-$1.2875-$7.59-$6.3025-$23.88$0.66 million$0.53 million3/12/2026Q4 2025SNDLSNDL$0.01$0.0291+$0.0191$0.03$257.97 million$183.87 million2/26/2026Q4 2025PBYIPuma Biotechnology$0.24$0.26+$0.02$0.26$68.60 million$75.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCUECue BiopharmaN/AN/AN/AN/AN/APBYIPuma BiotechnologyN/AN/AN/AN/AN/ASNDLSNDLN/AN/AN/AN/AN/ASRZNSurrozenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCUECue BiopharmaN/A2.742.74PBYIPuma BiotechnologyN/A2.381.93SNDLSNDL0.124.843.25SRZNSurrozenN/A11.9111.91Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCUECue Biopharma35.04%PBYIPuma Biotechnology61.29%SNDLSNDLN/ASRZNSurrozen66.57%Insider OwnershipCompanyInsider OwnershipCUECue Biopharma1.82%PBYIPuma Biotechnology22.20%SNDLSNDLN/ASRZNSurrozen31.74%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCUECue Biopharma603.94 million3.20 millionOptionablePBYIPuma Biotechnology20050.90 million39.60 millionOptionableSNDLSNDL2,751257.40 millionN/AOptionableSRZNSurrozen8011.61 million7.84 millionNot OptionableCUE, SNDL, PBYI, and SRZN HeadlinesRecent News About These CompaniesSurrozen (SRZN) price target increased by 10.11% to 43.522 hours ago | msn.comSurrozen Shareholders Support Board, Auditor and Pay PoliciesMay 14 at 4:50 PM | tipranks.comSurrozen to Present at Upcoming Healthcare Investor ConferenceMay 12 at 4:05 PM | globenewswire.comHC Wainwright Estimates Surrozen's Q2 Earnings (NASDAQ:SRZN)May 11, 2026 | marketbeat.comLifesci Capital Has Strong Forecast for Surrozen Q2 EarningsMay 11, 2026 | marketbeat.comRigel Pharmaceuticals (NASDAQ:RIGL) versus Surrozen (NASDAQ:SRZN) Head to Head ComparisonMay 10, 2026 | americanbankingnews.comWhat is Lifesci Capital's Forecast for Surrozen Q1 Earnings?May 8, 2026 | marketbeat.comSurrozen (NASDAQ:SRZN) Releases Earnings Results, Misses Estimates By $10.56 EPSMay 6, 2026 | marketbeat.comSurrozen Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 6, 2026 | globenewswire.comInsider Selling: Surrozen (NASDAQ:SRZN) VP Sells 1,584 Shares of StockMay 6, 2026 | insidertrades.comYang Li Sells 1,584 Shares of Surrozen (NASDAQ:SRZN) StockMay 5, 2026 | marketbeat.comSurrozen (NASDAQ:SRZN) COO Charles Williams Sells 2,036 SharesMay 5, 2026 | marketbeat.comSurrozen (NASDAQ:SRZN) CEO Craig Parker Sells 4,524 SharesMay 5, 2026 | marketbeat.comSurrozen (SRZN) Projected to Post Quarterly Earnings on FridayMay 1, 2026 | marketbeat.comSurrozen, Inc. (NASDAQ:SRZN) Sees Large Growth in Short InterestApril 29, 2026 | marketbeat.comSurrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)April 28, 2026 | globenewswire.comTD Cowen initiates coverage of Surrozen (SRZN) with buy recommendationApril 23, 2026 | msn.comSurrozen, Inc. (NASDAQ:SRZN) Receives Average Rating of "Moderate Buy" from BrokeragesApril 21, 2026 | marketbeat.comSurrozen (SRZN) Surges 5.9%: Is This an Indication of Further Gains?April 14, 2026 | zacks.comLifeSci Capital Keeps Their Buy Rating on Surrozen (SRZN)March 29, 2026 | theglobeandmail.comSurrozen (NASDAQ:SRZN) Major Shareholder Tcg Crossover Gp Ii, Llc Purchases 15,223 SharesMarch 26, 2026 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCUE, SNDL, PBYI, and SRZN Company DescriptionsCue Biopharma NASDAQ:CUE$25.33 -4.14 (-14.05%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$25.62 +0.29 (+1.14%) As of 05/14/2026 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.Puma Biotechnology NASDAQ:PBYI$7.19 +0.02 (+0.28%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$7.20 +0.00 (+0.07%) As of 05/14/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.SNDL NASDAQ:SNDL$1.46 +0.05 (+3.55%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$1.44 -0.02 (-1.37%) As of 05/14/2026 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.SNDL Inc. engages in the production, distribution, and sale of cannabis products in Canada. The company operates through Liquor Retail, Cannabis Retail, Cannabis Operations, and Investments segments. It engages in the cultivation, distribution, and sale of cannabis for the adult-use and medical markets; sells wines, beers, and spirits through wholly owned liquor stores; and private sale of recreational cannabis through wholly owned and franchised retail cannabis stores. In addition, the company produces and distributes inhalable products, such as flower, pre-rolls, and vapes. It offers its products under the Top Leaf, Sundial Cannabis, Palmetto, and Grasslands brands. The company was formerly known as Sundial Growers Inc. and changed its name to SNDL Inc. in July 2022. SNDL Inc. was incorporated in 2006 and is headquartered in Calgary, Canada.Surrozen NASDAQ:SRZN$29.87 -0.27 (-0.90%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$27.54 -2.34 (-7.82%) As of 05/14/2026 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas YETI Rallies After Earnings Beat and Raised Outlook Cisco’s Vertical Rally May Still Be in the Early Innings Dividend Growth or High Yield: The Income Investor's Bet Nebius Upside Expands as AI Feedback Loop Intensifies Oklo Stock Could Be Ready for Another Massive Run Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell Qualcomm Stock Doubles: New Era? Or Another False Start? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
